Get the Stockscreener App
0.2642
3.65%
0.0093
Pre-market:
.26
-0.0042
-1.59%
Cue Biopharma Inc stock is traded at $0.2642, with a volume of 653.01K.
It is up +3.65% in the last 24 hours and down -6.71% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.2549
Open:
$0.267
24h Volume:
653.01K
Relative Volume:
0.39
Market Cap:
$25.80M
Revenue:
$27.47M
Net Income/Loss:
$-26.60M
P/E Ratio:
-0.843
EPS:
-0.3134
Net Cash Flow:
$-21.86M
1W Performance:
-0.08%
1M Performance:
-6.71%
6M Performance:
-61.72%
1Y Performance:
-73.48%
1-Day Range:
$0.25
$0.269
1-Week Range:
$0.2378
$0.2789
52-Week Range:
$0.2302
$1.05
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.2642 | 25.80M | 27.47M | -26.60M | -21.86M | -0.3134 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Cue Biopharma Inc stock faces key test amid biotech volatility and pipeline progress - AD HOC NEWS
Cue Biopharma (CUE) Projected to Post Earnings on Monday - Defense World
Published on: 2026-03-21 13:01:47 - baoquankhu1.vn
Buyout Rumor: What chart patterns are forming on Cue Biopharma IncShare Buyback & Community Consensus Picks - baoquankhu1.vn
Certain Stock Incentive Plan of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Loss Report: Can Cue Biopharma Inc outperform in the next rallyIndex Update & Verified Momentum Stock Alerts - baoquankhu1.vn
Cue Biopharma (NASDAQ: CUE) files $300M shelf registration, $12.7M ATM via Jefferies - Stock Titan
Cue Biopharma 2024 Annual Report – Clinical-Stage Immunotherapy Pipeline, Regulatory Strategy, and Collaboration Highlights - Minichart
CUE SEC FilingsCue Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Report: Whats the RSI of Cue Biopharma Inc stockEarnings Growth Report & Smart Money Movement Alerts - baoquankhu1.vn
Cue Biopharma earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Cue Biopharma issues quarterly and annual earnings update - Traders Union
Cue Biopharma : Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - marketscreener.com
Reverse split on agenda as Cue Biopharma (CUE) plans 2026 virtual meeting - Stock Titan
Cue Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cue Biopharma (CUE) posts 2025 results and $15M ImmunoScape pact - Stock Titan
Cue Biopharma (CUE) pivots to autoimmune focus amid going concern risk - Stock Titan
Cue Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cue Biopharma (CUE) price target decreased by 20.00% to 4.08 - MSN
Published on: 2026-03-13 09:51:08 - baoquankhu1.vn
Cue Biopharma (CUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma (CUE) Unveils Promising CUE-401 Data at Global Con - GuruFocus
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
Bull Run: Can Cue Biopharma Inc disrupt its industryWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Cue Biopharma (NASDAQ: CUE) to vote on 1-for-30–1-for-50 reverse split - Stock Titan
CUE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Update Recap: Can Cue Biopharma Inc disrupt its industryPortfolio Update Report & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Momentum Shift: Whats the MACD signal for OSR Holdings Inc Equity WarrantBull Run & Long-Term Safe Investment Ideas - baoquankhu1.vn
Stock Market Recap: Will Cue Biopharma Inc benefit from geopolitical trendsJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
CUE Should I Buy - Intellectia AI
Cue Biopharma Sets 2026 Annual Meeting, Proposal Deadlines - TipRanks
Cue Biopharma sets April 13, 2026 annual meeting; February 28 deadline for shareholder proposals - TradingView
Cue’s CUE-401 well tolerated in mouse and NHP studies - BioWorld MedTech
Aug Technicals: Can Cue Biopharma Inc outperform in the next rallyJuly 2025 Levels & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Analyzing Cue Biopharma (NASDAQ:CUE) & Aardvark Therapeutics (NASDAQ:AARD) - Defense World
Autoimmune drug candidate CUE-401 passes early safety tests in animals - Stock Titan
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - Bitget
Can Cue Biopharma Inc. outperform in the next rally2025 Earnings Surprises & Growth Focused Entry Point Reports - mfd.ru
Cue Biopharma Names Lucinda Warren Chief Financial Officer - The Globe and Mail
How Cue Biopharma Inc. stock performs in rising dollar environmentWeekly Gains Report & Daily Risk Controlled Trade Plans - mfd.ru
Cue Biopharma appoints industry veteran Lucinda Warren as chief financial and business officer - marketscreener.com
Cue Biopharma (CUE) Appoints New Chief Financial and Business Of - GuruFocus
Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Financial Officer, Effective February 9, 2026 - marketscreener.com
Cue Biopharma Names Lucinda Warren Chief Financial And Business Officer - Nasdaq
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - Bitget
Cue Biopharma Appoints Lucinda Warren as Chief Financial and Business Officer - TradingView
Is Cue Biopharma Inc. stock attractive after correctionTreasury Yields & Short-Term High Return Ideas - mfd.ru
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):